Effects of Protoves-M1® and IPB-tre® on the prevention and the treatment of irritative symptoms after REZUM therapy of benign prostatic hyperplasia (BPH)
Abstract
Background: To analyze the role of Protopine and Nuciferine (Protoves-M1®) and IPB-tre® in the prevention and treatment of irritative symptoms after REZUM.
Materials and Methods: Fifty consecutive patients underwent REZUM between September 2020 and November 2022. All patients received a combined therapy with Protoves-M1® (Protopine and Nuciferine) syrup, 10 ml, once a day, and IPB-tre® 1 tablet/day two weeks before REZUM and for a period of 3 months, postoperatively and they were on medical therapy with alpha-blockers which were continued for 30 days after the procedure. Postoperative pain rating was assessed by visual analogue scale and efficacy and tolerability of therapy were evaluated by using Treatment Satisfaction Questionnaire for Medication (TSQM 1.4),
Results: Median age was 64.1 years old (interquartile range IQR 46-79) with a median prostate volume of 68.6 ml (IQR 40-160). The median operative time was 11.44 (IQR 7–16) minutes and patients received a median of 7.2 (IQR 4–14) PEEK vapor needle injections. After the interruption of anti-inflammatory therapy, we assisted in a significant decrease of VAS on the 10th postoperative day, with a median value of 1.6 (1-3). Median TSQM scores on effectiveness, side effect, convenience, and satisfaction were 75.2, 100.0, 82.5, and 85.9, respectively. Any grade of toxicity was reported.
Conclusions: A combined therapy with Protoves-M1® and IPB-tre® could be safe and efficient in reducing irritative symptoms after REZUM, even after the interruption of traditional anti-inflammatory therapy. Moreover, all patients reported a high level of satisfaction with the therapy in absence of side effects.
Keywords: Benign prostate hyperplasia, lower urinary symptoms, water vapor therapy, phytotherapy, outcomes